Heart Attack

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM...

Veradigm and American College of Cardiology Launch Influenza Vaccination Education Initiative to Improve Cardiovascular Health

CHICAGO--(BUSINESS WIRE)--#healthIT--Veradigm Inc. (NASDAQ: MDRX), a leading provider of healthcare data and technology solutions announced today the launch of TRANSFORM...

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a...

Cardio Diagnostics Holdings, Inc. Expands Partnership with Family Medicine Specialists to Bring Its Specialty Cardiology Tests to Select Walmart Supercenters

Agreement is the first introduction of AI-driven epigenetic heart attack risk assessment and coronary heart disease detection tests in a...

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize...

Comanche Biopharma Closes Oversubscribed $75 Million Series B Financing to Advance Mission to Develop and Make Globally Available the First Treatment Targeting a Root Cause of Preeclampsia

Tiziana Life Sciences Files New Patent Application for Combination Therapy of anti-CD3 (Foralumab) with GLP-1 Receptor Agonist for Additional Reduction of Obesity – Associated Inflammation

NEW YORK, Jan. 05, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...

CORRECTING and REPLACING Cardio Diagnostics Holdings, Inc. Unveils Groundbreaking Employer Cardiovascular Disease Risk Intelligence Platform, HeartRisk™

HeartRisk™ Empowers Employers Who Adopt Cardio Diagnostics’ Solutions to Proactively Combat Cardiovascular Disease in Their Workforce and Mitigate Business RisksCHICAGO--(BUSINESS...

American Medical Association (AMA) Grants Cardio Diagnostics a Dedicated CPT PLA Reimbursement Code for Epi+Gen CHD, an AI-powered Test for Assessing the Probability of a Heart Attack or Coronary Heart Disease Event

American Medical Association (AMA) Grants Cardio Diagnostics Holdings, Inc.’s AI-Powered Coronary Heart Disease Detection Test, PrecisionCHD, a Dedicated CPT PLA Reimbursement Code

Apnimed Announces First Patient Dosed in SynAIRgy, the Second Phase 3 Clinical Study of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100’s Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways

Atherosclerosis, an inflammatory disease characterized by buildup of cholesterol, lipids, and other substances (plaque) in arteries leading to heart attack...

American Medical Association is Reviewing Cardio Diagnostics Holdings, Inc’s Integrated Epigenetic-Genetic Cardiovascular Medicine Tests for CPT PLA Codes

CPT codes are critical to receiving reimbursement from federal and private payersCHICAGO--(BUSINESS WIRE)--Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), a leader...

Mineralys Therapeutics Further Defines Endotype-Specific, Targeted Approach to Treatment of Uncontrolled or Resistant Hypertension with Lorundrostat Data at AHA Scientific Sessions 2023

Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine

Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated...

As Daylight Saving Time Comes to a Close, Bausch Health Champions Mental Health with a Spotlight on Preventing Seasonal Affective Disorder (SAD)

Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...

error: Content is protected !!